This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Food distribution in Latin America === Food distribution in Latin America is mainly dominated by large distributors and chains. Efforts have been made to compete with the industrialization of the food distribution system through the establishment of four types of organizations: consumer purchasing organizations, consumer cooperatives, voluntary chains, and retailer purchasing associations. Consumer purchasing organizations are groups of families who buy food together. The benefits of joining one of these organizations are the reduced cost and improved variety in diet that comes from purchasing food with other families. Consumer cooperatives differ from consumer purchasing organizations in that they are constituted by groups of individuals who work together to secure high quality food for low prices. The cooperatives are analogous to a food union that actively works to secure the rights of its consumers. Voluntary chains are organizations of privately owned retailers and food wholesalers who operate as one economic body. These groups form contracts to work under, but are economically independent of one another. Retailer purchasing organizations are groups of retailers who purchase products as though they were a single buyer. Members within these organizations are all involved in the purchasing of goods, but do not form contracts.
==== Freeze-drying ==== This method is the most expensive out of all dehydration methods but provides the advantage of long stable shelf life at room temperature and an excellent retention of soluble nutrients (nitrogen protein and other solids). The product undergoes quick freeze at 10 °C (50 °F) and is then dried at a moderate temperature inside a strong vacuum. Due to the expensive nature of the equipment, the final product price is higher than tempeh preserved through other methods.
== Definition == The word Wagyu literally means "Japanese cattle" and does not denote a single breed. Before the modern breeds were established, Japan had regional populations of native cattle. After the Meiji Restoration in 1868, most were crossed for several generations with imported breeds, mainly British and continental European cattle. Two uncrossed native populations, the Mishima and Kuchinoshima cattle, survive and are considered to have remained free from European genetic influence. In modern Japanese breed and meat classifications, Wagyu usually means four breeds: the Japanese Black, Japanese Brown, Japanese Polled, and Japanese Shorthorn. Beginning in the late nineteenth century, these breeds developed from regional native cattle crossed with imported stock. The imported breeds used differed by breed and region. The resulting cattle were later established as distinct breeds through selection and closed breeding. After bovine spongiform encephalopathy (BSE) was first confirmed in Japan in 2001, the Beef Traceability Law was enacted in 2003. The system assigns each animal a ten-digit identification number and records its birth and movements; it applies to all cattle in Japan, not only Wagyu. This system is also used to verify the labeling requirements introduced for Wagyu beef in 2007. Under guidelines issued by the Ministry of Agriculture, Forestry and Fisheries, the designation Wagyu is recommended only for beef from cattle documented as one of the four breeds or specified crosses between them and confirmed as having been born and raised in Japan.
Luteinizing hormone is available mixed with FSH in the form of menotropin, and other forms of urinary gonadotropins. More purified forms of urinary gonadotropins may reduce the LH portion in relation to FSH. Recombinant luteinizing hormone is available as lutropin alfa (Luveris).
Among the 16 genes, the analysis identified two for which rare mutations are known to cause monogenic obesity: MC4R and PCSK1 (proprotein convertase subtilisin/kexin type 1). One study provides genetic evidence linking rare coding variation to BMI and obesity-related phenotypes. MC4R gene mutations are associated with early-onset severe obesity. The effect of two exemplary heterozygous coding variants in the MC4R gene (C293R and S94N) are: • Rapid weight gains from early age (the most important feature). • Development of severe obesity (BMI ≫97th percentile) at early ages, usually <3 years of age. • Persistent food-seeking behavior, mostly reported from six months of age. • Parental/siblings anthropometric data: suspect if relatives present normal anthropometric data. • Tall stature/increased growth velocity (MC4R monogenic diabetes). There is limited treatment options for the most common form of monogenic obesity, MC4R mutations symptoms can be treated with a Glucagon-like Peptide-1 Receptor Agonist liraglutide which cause weight loss by reducing appetite. They found that the effects of liraglutide 3.0 mg daily for 16 weeks causes weight reducing and glucose lowering and may be relevant treatment in the most common form of monogenic obesity.
Sources: en.wikipedia.org
Due to the shorter distance to be travelled in the United Kingdom, the need for refrigeration was limited to specialised goods, which could in express-train format - mostly run overnight to avoid delays from passenger traffic - be transported in suitable timescales of less than a day from the area of production to processing, or onwards to the point of consumer consumption. Hence, whilst similar shipping requirements for cattle, fish, fruit, and farm-fresh produce existed, the need for refrigeration was often minimized by using non-stop express train service to the required destination. For example, the London Midland and Scottish Railway ran specialized express trains from meat producer hubs in Scotland and the North of England to the Smithfield Meat Market in London, with a dedicated goods station located below ground level directly into the market's slaughtering house. The LMS and the LNER also ran express fish trains from Fleetwood and Grimsby to Broad Street to access Billingsgate Fish Market. The big four railway companies standardized their ice-chilled wagons within their own networks, which were built with more insulation, further minimizing the need for onboard mechanical refrigeration. The Great Western Railway designed and built their own Mica A (ventilated) and Mica B (Non-ventilated) vans for such express produce trains, with ice supplied by the original product producer from their own plant.
By 2015, the average fiber content per pack of MRE has improved to an adequate 12 grams. A superstition exists among troops about the Charms candies that come with some menus: they are considered bad luck, especially if actually eaten. In March 2007, The Salt Lake Tribune invited three gourmet chefs to taste-test 18 MRE meals. None of the meals rated higher than a 5.7 average on a scale of 1 to 10, and the chicken fajita meal in particular was singled out for disdain, rating an average score of 1.3. In 2010, the New York Times reported that a French combat ration (such as cassoulet with accompaniments of deer pâté and nougat) could be traded for around five MREs, though by 2014 it was claimed that MRE menus had improved to the point that their worth had reversed. The vegetable cheese omelet MRE, Recipe No. 4, introduced in 2005, is generally considered the worst ever. Soldiers serving in Iraq dubbed it the "Vomelet" (a pun with vomit), both for its appearance and taste. It was discontinued in 2009.
The most studied ring destructive pathway is the Kodama pathway and it was initially identified in Pseudomonas abikonensis and Pseudomonas jijani. The pathway comprises four main steps: i) the successive hydroxylation by NADH-dependent dioxygenases of the carbons in one of the aromatic rings, followed by ii) the dehydrogenation of the ring by a NAD+ cofactor and further iii) oxygenation promoting ring cleavage and formation of a pyruvyl branch; concluding with iv) the hydrolysis of the pyruvyl substituent to release pyruvate and the remaining of the substrate. Since the end products of the pathway are still water soluble sulfur compounds, the pathway has often been disregarded as an appealing pathway for industrial applications, in particular by the oil industry. The most well-studied sulfur specific pathway is the 4S pathway, first discovered in the bacterium Rhodococcus erythropolis (strain IGTS8), which was observed to remove sulfur from dibenzothiophenes and derivatives in three steps: i) a double oxidation of the sulfur (to sulfoxide and sulfone) performed by a flavin-dependent monoxygenase, followed by ii) a carbon-sulfur bond cleavage by a second flavin-dependent monoxygenase and a iii) desulfination reaction through which 2-hydroxybiphenyl and sulfite are produced.
=== Tom Wolsey === Tom Wolsey (Harry Hadden-Paton) is the newly-appointed CEO of Pierpoint, brought on to help steer the firm through its debt crisis. Tom assembles an emergency committee of senior executives to help salvage Pierpoint when its stock plummets the day of its 150th anniversary. After several failed attempts to find a buyer for the firm, Eric finally brokers a sale with Al-Mi'raj, a firm representing the Egyptian sovereign wealth fund. Tom is fired as CEO because the Egyptian government would not approve of his homosexuality.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.